#Liquid biopsy

[marketdevelopment]

Liquid Biopsy Market Latest Innovations, Drivers and Industry Status 2023 to 2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

A liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing various biomarkers (such as circulating tumor cells, cell-free DNA, exosomes, and other nucleic acids) found in bodily fluids like blood, urine, or saliva. It's primarily used for the detection and monitoring of diseases, particularly cancer.

Advances in technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR have greatly enhanced the sensitivity and specificity of liquid biopsy tests, enabling more accurate detection and monitoring of diseases.

Liquid biopsies have gained particular attention in the field of oncology for early cancer detection, monitoring treatment response, and detecting resistance mutations. They offer a non-invasive alternative to tissue biopsies and can provide real-time information on tumor dynamics.

While oncology remains the primary focus of liquid biopsy applications, researchers and companies have been exploring its potential in other areas such as prenatal testing, infectious disease diagnostics, transplant monitoring, and autoimmune disease detection.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading players involved in the Liquid Biopsy Market include:

Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States), Beckman Coulter(United States), Illumina (United States), PerkinElmer (United States), Becton, Dickinson and Company (BD) (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Cancer Genetics, Inc. (United States), Myriad Genetics, Inc. (United States) 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

If You Have Any Query Liquid Biopsy Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/16300

Segmentation of Liquid Biopsy Market:

By Cancer Type

Lung

Breast

Liver

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cells

By End-User

Hospitals

Laboratories

Government Research Centre

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Key Reasons To Invest In Liquid Biopsy Market Report:

To provide a complete structure and a basic overview of the Liquid Biopsy market.

To provide insights into important Liquid Biopsy aspects such as growth trajectory, CAGR value, market share, and revenue analysis.

Assess growth opportunities, threats, market drivers, and associated risks.

To understand the Liquid Biopsy market competition by analysing the top business people along with market profiles, import/export details, revenue, profit, and market shares.

Indicate pricing structure, import/export details, supply chain analysis, SWOT analysis to facilitate key decision-making process.

Analysing emerging Liquid Biopsy market segments and sub-segments to drive ultimate growth, investment analysis, and future growth opportunities.

Understand sources of knowledge, intended research methodology, and important conclusions.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[drforambhuta]

Utilization of Precision Oncology in Breast Cancer Management

The implementation of precision oncology has transformed the approach to treating breast cancer across its various subtypes, presenting novel pathways for tailored therapeutic interventions and individualized treatment methodologies. Key facets of applying precision oncology in breast cancer management encompass:

1. Tailored Treatments: Precision oncology facilitates the recognition of actionable molecular targets like HER2 amplification or mutations in genes such as BRCA1/2. Therapeutic interventions, such as HER2-targeted medications (e.g., trastuzumab) or PARP inhibitors (e.g., olaparib), selectively impede aberrant signaling pathways or exploit vulnerabilities in cancer cells, thereby enhancing treatment efficacy and minimizing adverse effects compared to conventional chemotherapy.

2. Immunotherapy: Immune checkpoint inhibitors, which harness the body's immune response to combat cancer cells, have emerged as a promising therapeutic avenue in breast cancer. Precision oncology aids in identifying individuals likely to benefit from immunotherapy based on specific biomarkers like PD-L1 expression or tumor mutational burden (TMB).

3. Understanding Resistance Mechanisms: Resistance to conventional therapies poses a significant obstacle in breast cancer management. Precision oncology elucidates the mechanisms behind treatment resistance by pinpointing secondary mutations or alternative signaling pathways activated in resistant tumors. This comprehension informs the development of combination therapies or innovative treatment modalities to surmount resistance and enhance patient outcomes.

4. Tailoring Clinical Trials: Precision oncology facilitates the design of clinical trials targeting precise molecular subtypes or genetic alterations in breast cancer. Basket trials, which enroll participants based on shared molecular characteristics rather than tumor types, enable the evaluation of targeted therapies across diverse cancer types, expediting drug discovery and development.

5. Liquid Biopsies: In addition to conventional tissue biopsies, precision oncology harnesses liquid biopsies like circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) to monitor disease progression, detect minimal residual disease, and identify treatment resistance. Liquid biopsies offer a minimally invasive and real-time approach to assessing tumor dynamics and informing treatment decisions.

6. Risk Assessment and Prevention: Precision oncology extends beyond treatment to encompass risk assessment and preventive strategies. By analyzing germline and somatic mutations linked to breast cancer predisposition, precision oncology identifies individuals at heightened risk of developing the disease. This enables personalized screening protocols, risk-reducing interventions, and targeted preventive measures like chemoprevention or prophylactic surgery to mitigate the risk of breast cancer onset.

7. Psychosocial Support and Survivorship: Precision oncology underscores the significance of comprehensive care, encompassing psychosocial support and survivorship programs. A cancer diagnosis can exert profound psychological and emotional effects on patients and their loved ones. Precision oncology integrates psychosocial interventions such as counseling, support groups, and survivorship care plans to address the emotional, social, and practical needs of patients throughout their cancer journey.

Doctors suggest undergoing regular health checkups for the diagnosis of conditions like cancer at their early stage. There are many good hospitals in India that offer a full body health checkup package for the early detection and management of breast cancer.

[pathologylab]

In the realm of #personalized medicine, #G2M offers Liquid Biopsy NGS #Panels, which stand out as revolutionary tools, offering unprecedented levels of sensitivity at a fraction of the traditional cost. These panels represent a cutting-edge approach to detecting and monitoring various diseases, including #colorectal, breast, and lung #cancer, with remarkable precision and efficiency.

Unlike conventional tissue biopsies, which can be invasive, time-consuming, and sometimes challenging to obtain, our liquid biopsy panels offer a minimally invasive alternative approach that can be performed more frequently, allowing for real-time #monitoring of disease progression and treatment response.

Visit our website for more information https://www.genes2me.com/next-generation-sequencing-clinical-panels/cancer-diagnosis-dna-Panels

To know more about these NGS Panels, contact us at social@genes2me.com or call us +91-8800821778.

#genes2me #lungcancer #disease #liquidbiopsy #breastcancer #lungcancer #colorectalcancer #ctdna #dna #dnasequencing #madeinindia #manufacturing #nextgenerationsequencing #nextgeneration #india

[kirancmi]

Liquid Biopsy Is Estimated To Witness High Growth Owing To Ease Of Use And Non-Invasive Process

Liquid biopsy is a non-invasive alternative to surgical biopsy that analyzes blood samples to diagnose cancer and other diseases. It allows doctors to detect cancer recurrence earlier and monitor treatment effectiveness with simple blood draws, instead of painful tissue biopsies. The global liquid biopsy market includes products and services required for liquid biopsy testing including reagents and kits, instruments, and services. The technology is useful for monitoring disease progression and identifying therapeutic options for advance stage cancer patients.

The global liquid biopsy Market is estimated to be valued at US$ 5.25 Bn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The global liquid biopsy market is witnessing significant growth owing to the ease of use and non-invasive process of liquid biopsy as compared to traditional tissue biopsy. As liquid biopsy relies on blood draws it eliminates risks associated with surgical biopsies like infection, scarring, and pain. This has increased adoption amongst patients and healthcare providers for early cancer detection and monitoring. Further, ongoing research and development of liquid biopsy technologies especially for detection of multiple cancer types from a single blood draw is also driving market growth. Various players are focused on development of assays and tests with high sensitivity and specificity to detect even minimum traces of circulating tumor DNA (ctDNA) in bloodstream. However, complex regulatory processes and reimbursement challenges remains a restraining factor in market growth. Liquid biopsy is yet to gain approval for screening of early cancer detection from regulatory bodies. Lack of reimbursement policies also hinders widespread clinical adoption. Nevertheless, ongoing approvals and establishment of reimbursement codes is expected to address these challenges in coming years propelling liquid biopsy market growth. SWOT Analysis Strength: The liquid biopsy market offers non-invasive and cost-effective alternatives to tissue biopsy. It can detect multiple types of cancer from a simple blood draw. This reduces risks associated with invasive surgical biopsy procedures. Liquid biopsy also enables longitudinal monitoring of cancer during and after treatment from blood draws. Weakness: Liquid biopsy tests still need improvements to achieve accuracy levels comparable to tissue biopsy. False positive and false negative results are possible challenges. Limited clinical evidence also means liquid biopsy may not be reimbursed or accepted by regulatory agencies for certain clinical uses. Opportunity: The rising cancer burden worldwide generates vast opportunities for liquid biopsy adoption. Early cancer screening and detection is a key growth driver. Liquid biopsy provides hope for precision and personalized cancer monitoring and management. Growing investments in cancer research support liquid biopsy commercialization. Threats: Intellectual property disputes between companies could impact liquid biopsy innovations. Slow regulatory approvals may limit timely commercialization. Established diagnostic procedures pose competition. Reimbursement policies influence market acceptance. Key Takeaways The global liquid biopsy market size is expected to witness high growth. It is estimated to reach a value of US$ 5.25 billion by 2024, registering a CAGR of 6.7% during the forecast period of 2023 to 2030.

North America currently dominates the market due to rising healthcare investments and growing focus on precision medicine in oncology. Asia Pacific is expected to offer lucrative opportunities owing to increasing cancer incidence, growing healthcare expenditure, and expanding biotechnology industry in countries like China and India. Key players

 operating in the liquid biopsy market are BASF SE, Spectrum Chemical Manufacturing Corp., Kudos Chemie Limited, AVT Natural Products, Tianjin Zhong€TMan, Pharmaceutical Company Ltd., Shandong Xinhua Pharma, Aarti Industries Limited, Bakul Group, Taj Pharmaceuticals Limited., and Jilin Shulan Synthetic Pharmaceutical Co. Ltd. The market is fairly consolidated with large corporations having wide geographical presence and strong foothold. However, small players contribute significantly through novel technologies and regional expertise. Strategic collaborations between companies allow leveraging complementary strengths to commercialize new liquid biopsy applications. Overall, the rapidly evolving oncology diagnostics domain presents immense growth potential for liquid biopsy.

Get more insights on this topic: https://www.newsstatix.com/liquid-biopsy-market-industry-insights-trends-liquid-biopsy-market/

Explore more information on this topic, Please visit: https://allmeaninginhindi.com/navigating-the-evolving-landscape-of-enterprise-artificial-intelligence-solutions/

[market-insider]

Liquid Biopsy: Evolving Trends in Breast Cancer

The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth. With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment.

Breast Cancer Liquid Biopsy Market Report Highlights

In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer

The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment

Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection

Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population

Gain deeper insights on the market and receive your free copy with TOC now @: Breast Cancer Liquid Biopsy Market Report

There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

[oncodxrx]

OncoDxRx’s PGA assay is revolutionary with gene-drug matchmaker capability

OncoDxRx’s PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) innovation will include disruptive technologies, with high-performance liquid biopsy platform supported by big data algorithms.

The Los Angeles-based liquid biopsy company’s PGA assay will provide therapy guidance for those patients currently not responding to targeted treatment as it detects, matches and ranks efficacies of existing anticancer drugs for each individual patient based on his/her own gene expression signature.

The company has developed a set of disruptive technologies that will ensure the test superiority of liquid biopsy in the years ahead. New broad-format panels housing multiple biomarkers will provide unparalleled levels of precision in their drug matching capabilities.

The new platform will generate significantly larger volumes of gene expression data from both tumor and non-tumor tissues. The in silico data processing system (screening, matching, identifying, ranking) will use advanced Big Data algorithm, with intuitive user interfaces to optimise operator workload and provide decision support.

The latest innovations developed by dedicated OncoDxRx scientists for the current and future generations of liquid biopsy will provide the company with a comprehensive roadmap of the circulating cell-free transcriptomics to meet current and future clinical needs, helping to consolidate its position as one of the world’s leading cell-free mRNA company.

[emergeresearch]

Liquid Biopsy Market Demand, Scope, Share, Growth, Applications, Types and Forecasts Report 2030

Emergen Research’s latest market research report focuses on the global Liquid Biopsy market, and the report provides in-depth analysis of each of its major segments. Reports about the global Liquid Biopsy market provide a comprehensive overview of the market, including market size, revenue growth rate, industry statistics, revenue shares among regional markets, gross profits, production costs,…

[bisresearchreports]

Liquid biopsy is a non-invasive medical procedure which holds the ability to detect the presence of molecular cancer biomarkers in biological fluids. Liquid biopsy has a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics. Significant increase in the research and development activities pertaining to next-generation sequencing are underway to develop NGS products and services, which are expected to increase due to the rising number of chronic disease burdens such as cancer

[medi-techinsights]

Global Liquid Biopsy Market is poised to witness a decent CAGR of 17% by 2026

Liquid Biopsy is a procedure of sampling and analyzing non-solid biological tissues, for the screening of cancer and other inflammatory conditions, associated with cardiac and other medical disorders. The sampling procedures are minimally invasive, quick and incur minimal patient pain and risk. Liquid Biopsy also helps in the early diagnosis of various types of cancers such as breast cancer, non-small cell lung carcinoma, lymphomas, head and neck cancer, and leukemia.

Advent of Advanced Technologies for Liquid Biopsy Drives the Global Liquid Biopsy Market

Liquid biopsy is an emerging technology and has the potential to revolutionize early cancer detection by analyzing available ctDNA for specific mutation profiles, fragmentation patterns, and methylation signatures. The significant developments in a digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies has led to a significant reduction in sequencing cost with the improvement in the accuracy of liquid biopsy. Further advancements in technology are expected to trigger the growth of the market in the coming years.

Adoption of Circulating Biomarkers for Early Detection and Screening of Cancer

Presently,  circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are the most commonly used liquid biopsy-derived biomarkers. In the recent years, CTCs have gained immense significance in detecting tumors, replacing invasive tissue biopsies not only due to their ease in sampling but also in providing data regarding tumor conditions in a ‘real-time’ manner. CTCs can also be used in vivo for the generation of patient-derived tumor models that assist in treatments.

“Liquid Biopsy is a dynamic and continuously evolving field. Technological advancements directed towards faster and more convenient diagnosis will drive the market. Liquid biopsies could be a game-changer in cancer testing.” - Head of Diagnostic Biomarkers, Liquid Biopsy Company, United States

Upcoming Market Challenges: Liquid Biopsy Market

Some of the major challenges restricting the growth of the liquid biopsy market are stringent government regulations, suboptimal patient adherence, low sensitivity for early-stage disease, and high false-positive rates. The wrong diagnosis can lead to false-negative results which can impact the informative value of the liquid biopsy tests for cancer.

North America Leads the Adoption of Liquid Biopsy Market

From a geographical perspective, North America holds the largest share of the liquid biopsy market. The growing prevalence of cancer cases in US population, adoption of liquid biopsy for the diagnosis of cancer, patient preference for non-invasive diagnosis and monitoring and the presence of key players in this region are some of the key factors driving the market growth.

Competitive Landscape Analysis: Global Liquid Biopsy Market

Some of the top players operating in the global liquid biopsy market are F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Guardant Health Inc., MDxHealth SA, and Illumina Inc., among others.

Get Customized Research Report on Liquid Biopsy Market @ https://meditechinsights.com/liquid-biopsy-market/

[pathologylab]

#G2M brings you the newly launched, highly #automated & user friendly software and workstation which can ensure a streamlined and effortless #NGS library preparation. The workstation can construct 24 libraries in one run over a short span of time, thus providing you with a good library preparation experience.

Contact us at social@genes2me.com or +91 8800821778 to know more about this revolutionary NGS #solution.

#nextgenerationsequencing #bioinformatics #genomics #ngspanels #panels #analysis #software #sequencing #research #liquidbiopsy #ngsanalysis #genomics #biotech #biotechnology #bioinformatics #yearsofexcellence #data #bioindia #dna #rna #genetics #liquidbiopsy #sequencing #genome #genomeanalysis #molecularbiology #genes2me

[goffcline6]

Don't Give Up! Uplifting Advice For The Cancer Fight

Most of us will inevitably go through our lives without stressing too much over diseases like cancer. We all know that being a worrywart is just a waste of time. However, some people outright avoid learning about cancer because it's a road they refuse to travel down. You cannot have this attitude. You should always learn about the topic, and here is some great information on it. The sun can be a major cancer causing factor for many people. The sun releases ultraviolet rays that enter the earth's atmosphere. When we step outside, our skin is exposed to these rays, and too much exposure can cause skin damage that can lead to skin cancer. Be sure to protect yourself with sun screen to prevent this. Sit down and go over your goals and priorities. A cancer diagnosis provides a good reason to re-evaluate and reflect on your life. Some things that were important may no longer be as important as they were before. Are there activities that you have been thinking of doing or people you haven't seen that you would like to? When someone close to you has cancer, it is important to let them know you are available. Although TARGT First may be hard to do, your loved one will appreciate the opportunity to talk through their feelings with someone who cares. Give them the opportunity for free expression without interjecting your own thoughts and opinions. People who suspect they may have cancer should rush to the doctor right away to get properly diagnosed. The earlier the cancer is caught in the body, the better your odds are of beating this terrible disease and living a normal life. Early stages of cancer can be defeated with therapy and/or surgery. You need to know the symptoms of certain kinds of cancer, for instance colon cancer, because your best chance of surviving is to catch them early. Sudden weight loss, cramping, thin stools and stools that contain blood are all symptoms of colon cancer. If you are experiencing these symptoms, check with your doctor immediately. If someone you know has contracted cancer, the best thing you can do now is listen to this person's wants and needs. Trying to insert yourself into their life by force may backfire and cause this person to reject you, and treating this person differently may have a devastating effect. Listen to their needs. If you have cancer or if someone you love has the disease, one of the first things you should do is work to deal with your own feelings on the matter. Do not allow for any negative feelings to bleed over into someone else's life. Face those fears head on and work on keeping those emotions at bay. You'll have to develop an intimate relationship of sorts with people you'd rather not get to know: medical personnel who are helping treat your cancer. These helpers are medical professions, such as doctors and nurses. They also include aides and counselors and administrative personnel. Graciously allow these people to help you, because you can't face cancer alone. You're going to be running back and forth to the bathroom a lot as you fight with your cancer, so move into any bedroom that's closest to a bathroom. Being in close proximity to a bathroom will help to prevent accidents, and you also have quick and direct access to the shower when you need to freshen up. Try putting a seal on older wood playground equipment. Arsenic pesticides were placed on many deck and playground products prior to 2005. Prevent contact with these potentially dangerous materials by using a good quality sealant. If someone close to you has cancer, accompany them on their doctor's visits. Talk to their doctor about any questions or concerns you might have. You are likely to have some that your relative does not ask, and if you get answers, you are better able to be a good caretaker. Just because you're learning about how to prevent and how to treat cancer, that in no way means that you have to stress over catching it or worry about every little item you're putting into your body. Put your fears aside for a minute and take the time to learn about your options. Remember what you've read here and be prepared to use it if the time ever comes.

[renubresearch]

Liquid Biopsy Market is expected to reach US$ 10.08 Billion by 2030

Renub Research has released a report titled “Global Liquid Biopsy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030,” which includes market percentage records and a thorough enterprise analysis. This report looks at the global liquid biopsy market’s competition, geographic distribution, and growth potential. Expert Insights: Ask Analyst or Download Full Report…

[bhushans]

Meeting the Needs of a Growing Population: The Evolving Global Liquid Biopsy Market

The global liquid biopsy market is positioned for rapid expansion, with an estimated revenue of USD 1,538.3 million in 2023. According to insights from healthcare domain experts, providers in the liquid biopsy sector can anticipate a robust Compound Annual Growth Rate (CAGR) of 21.7% through 2033. By the end of the forecast period, the market is projected to achieve a valuation of USD 10,938.6 million, reflecting significant growth opportunities within the healthcare industry.

Liquid biopsy, a non-invasive diagnostic technique that detects biomarkers and genetic material in bodily fluids, is revolutionizing cancer diagnosis, monitoring, and treatment. This innovative approach offers several advantages over traditional tissue biopsy, including real-time monitoring, early detection of treatment response or resistance, and the ability to capture tumor heterogeneity

Tumor tissue is currently the gold standard for determining the kind and stage of cancer. Important players are attempting to reduce the current obstacles to its utilization in order to increase its potential applications in the future. The feasibility of liquid biopsy techniques for identifying cancer patients’ genetic profiles has also been shown by a number of research. The studies carefully take into account the reactions in order to track the course of treatment and identify any early warning symptoms of therapeutic resistance.

Request Your Detailed Report Sample With Your Work Email : https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.

“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.

Key Takeaways from the Liquid Biopsy Market Report

The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.

The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.

In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.

In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.

CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.

By sample type, blood sample type holds prominence in the liquid biopsy market.

Key Developments by Liquid Biopsy Market Players

QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.

Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.

Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).

Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.

Key Companies Profiled:

BIOCEPT, INC.

Qiagen N.V.

Trovagene, Inc

Janssen Global Services, LLC

MDxHealth SA

Natera, Inc

F. Hoffmann-La Roche Ltd

Silicon Biosystems

Pathway Genomics Corporation

Sysmex Corporation

Others

Key Segments Profiled in the Liquid Biopsy Industry Survey:

By Biomarker Type:

CTCs (Circulating Tumour Cells)

ctNA (Circulating tumor Nucleic Acids)

Exosomes

By Sample Type:

Blood Liquid Biopsy

Urine Liquid Biopsy

Other (Plasma, Saliva, CSF) Liquid Biopsy

By Application Type:

Liquid Biopsy for Lung Cancer

Liquid Biopsy for Gastrointestinal Cancer

Liquid Biopsy for Prostate Cancer

Liquid Biopsy for Breast Cancer

Liquid Biopsy for Colorectal Cancer

Liquid Biopsy for Leukemia

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

Middle East and Africa

[univdatosmarket]

Liquid Biopsy Market was valued at ~US$ 1 billion in 2020 and is expected to grow at a CAGR of ~20% over the forecast period (2021-2027)